All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

The majority of current pediatric acute lymphoblastic leukemia (ALL) cases have a high long-term survival rate due to the recent advances in treatment using multiple chemotherapeutic agents including L-asparaginase (L-asp) \[[@pone.0136428.ref001]\]. Since Hill et al first used L-asp in 1967 \[[@pone.0136428.ref002]\], it has been established as the \"key drug\" for this disease \[[@pone.0136428.ref003]--[@pone.0136428.ref006]\]. In addition, a high dose of L-asp is currently used to treat adolescent and young adult (AYA) patients with ALL because the pediatric ALL protocol is superior to the adult protocol for treatment of AYA patients \[[@pone.0136428.ref007], [@pone.0136428.ref008]\]. However, this agent is associated with various complications, including pancreatitis, thrombosis, hypersensitivity, and metabolic disorders \[[@pone.0136428.ref009]--[@pone.0136428.ref011]\]. Loeb E et al first reported L-asp-induced hyperglycemia in 1970 \[[@pone.0136428.ref012]\], and impaired glucose tolerance develops in 10% of ALL patients treated with L-asp \[[@pone.0136428.ref013]--[@pone.0136428.ref016]\]. Severe conditions associated with hyperglycemia, such as diabetic ketoacidosis, may require temporary withdrawal of chemotherapy. Although several studies have determined the obesity, which was surrogate marker for insulin resistance, was the risk factors for L-asp-related hyperglycemia in western countries \[[@pone.0136428.ref015], [@pone.0136428.ref016]\], the profile of adverse events caused by L-asp, especially hyperglycemia may be influenced by ethnicity, schedule/dose of L-asp and concomitant use of steroid \[[@pone.0136428.ref017]\]. However, these factors have not been studied in large cohort. The purpose of this study was to identify the clinical features and risk factors for L-asp-related hyperglycemia in 1,176 pediatric ALL patients registered in the Japan Association of Childhood Leukemia Study (JACLS) ALL-02 study using protracted L-asp administration in maintenance phase for the patients older than 10 years.

Methods {#sec002}
=======

Ethical statement {#sec003}
-----------------

The written informed consent was obtained from the patients' guardians according to the Declaration of Helsinki, and the treatment protocols were approved by the institutional review boards of National Hospital Organization Nagoya Medical Center and the participating institutes.

Patient cohort and treatment {#sec004}
----------------------------

A total of 1,252 patients (aged 1--18 years) with newly diagnosed ALL were enrolled in the JACLS ALL-02 study from April 2002 to May 2008 \[[@pone.0136428.ref006], [@pone.0136428.ref018]\]. The median follow up period of our patients was 62 months. Patients with Ph+ ALL, mature B ALL, infant ALL, and natural killer cell leukaemia were excluded. Participants were stratified into standard risk (SR), high risk (HR), extremely high risk (ER), T cell type ALL (T), and induction failure (F) groups according to patient characteristics (**[S1 Fig](#pone.0136428.s001){ref-type="supplementary-material"})**. Seventy-six patients were removed from the analysis due to the reasons described in **[Fig 1A](#pone.0136428.g001){ref-type="fig"}.** The characteristics of the remaining 1,176 patients (SR = 386, HR = 509, ER = 128, T = 78, and F = 75) were then analyzed (**[Table 1](#pone.0136428.t001){ref-type="table"})**.

![Design of the study and patient flow.\
(A) during the entire protocol and the induction phase. No height and weight data were recorded on the case report form at the Data Center for 72 cases. The remaining 1,104 cases were used for obesity analysis. (B) No height and weight data were recorded on the case report form at the Data Center for 51 cases during the re-induction phase. The remaining 897 cases were used for obesity analysis. (C) No height and weight data were recorded on the case report form at the Data Center for 37 HR, ER, and T patients during the maintenance phase. The remaining 552 cases were used for obesity analysis.](pone.0136428.g001){#pone.0136428.g001}

10.1371/journal.pone.0136428.t001

###### Characteristics of the 1,176 patients.

![](pone.0136428.t001){#pone.0136428.t001g}

  Features at diagnosis                            Risk group                                                                                                         
  ------------------------ ----------------------- ------------------- ------------------ ------------------ ------------------ ------------------ ------------------ -------
  Age (year)               Average ± SD (median)   4.1 ± 2.1 (4)       6.3 ± 4.3 (5)      7.0 ± 4.2 (6)      8.0 ± 3.5 (8)      7.7 ± 4.4 (7)      5.8 ± 3.9 (5)      
  at onset                 \< 10                   386                 370                89                 53                 47                 945                
                           ≥ 10                    0                   139                39                 25                 28                 231                
  Sex                      Female                  195                 232                60                 11                 28                 526                
  Male                     191                     277                 68                 67                 47                 650                                   
  Immuno-phenotype         B-cell                  386                 509                98                 0                  39                 1,032              
  Mixed                    0                       0                   25                 0                  13                 38                                    
                           T-cell                  0                   0                  0                  78                 21                 99                 
                           Undifferentiated        0                   0                  5                  0                  2                  7                  
  Leukocyte count          Range (median)          0.37--9.98 (3.70)   0.43--401 (13.2)   1.00--420 (19.1)   0.72--819 (54.4)   1.10--816 (31.3)   0.72--819 (7.50)   
  at onset (× 10^9^/L)     \< 20                   386                 317                69                 26                 31                 829                
                           ≥ 20-\< 50              0                   115                31                 11                 18                 175                
                           ≥ 50                    0                   77                 28                 41                 26                 172                
  Chromosome/              Normal karyotype        189                 203                56                 44                 28                 520                
  Genetic abnormality      Hyperdiploid            99                  97                 17                 1                  2                  216                
                           *ETV6-RUNX1*            87                  88                 17                 0                  3                  195                
                           *TCF3-PBX1*             0                   68                 8                  0                  2                  78                 
  Extramedullary disease   Present                 0                   18                 5                  9                  5                  37                 
  Obesity                  BMI                     \< 22%              361                461                114                68                 63                 1,067
  ≥ 22%                    3                       19                  8                  2                  5                  37                                    
  BMIp                     \< 85%                  324                 398                100                58                 59                 939                
  ≥ 85%                    40                      82                  22                 12                 9                  165                                   
  Obesity index            \< 20%                  353                 444                111                64                 63                 1,035              
  ≥ 20%                    11                      36                  11                 6                  5                  69                                    
  No data                                          22                  29                 6                  8                  7                  72                 
  Down syndrome            Present                 6                   10                 5                  0                  2                  23                 

ER, extremely high risk; F, induction failure; HR, high risk; L, liter; SD, standard deviation; SR, standard risk

T, T-cell type; n, number; SD, standard deviation.

The L-asp administration schedule according to the JACLS ALL-02 protocol is summarized in **Tables A-E in [S1 File](#pone.0136428.s003){ref-type="supplementary-material"}**. The naïve *E*. *coli* L-asp preparation, i.e., Leunase (Kyowa Hakko Kirin, Tokyo, Japan) was used because PEG asparaginase has not been approved in Japan. Generally, L-asp was administered with prednisolone (PSL) (40 mg/m^2^), not dexamethasone (DEX), in this protocol. Protracted administration of L-asp in maintenance phase was employed in HR, ER and T-ALL protocol.

Evaluation of risk factors for L-asp-related hyperglycemia {#sec005}
----------------------------------------------------------

During the protocol study, adverse events were assessed according to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 2.0 and reported to the Data Center. L-asp-related hyperglycemia was defined as grade 3 or 4 hyperglycemia (serum glucose\>250 mg/dl) occurring during L-asp treatment. Hyperglycemia due to L-asp-related pancreatitis was excluded. The risk factors for L-asp-related hyperglycemia were analyzed during the entire protocol: the induction phase, the re-induction phase, and the maintenance phase for HR, ER and T-ALL patients (**[Fig 1A--1C](#pone.0136428.g001){ref-type="fig"}**). The relationship between obesity and L-asp-related hyperglycemia was analyzed in 1,104 patients only due to a lack of height and weight data for 72 patients.

The characteristics of the 72 patients who lacked data did not differ from those of the remaining patients except for leukocyte count at onset and central nervous system status (**Table F in [S1 File](#pone.0136428.s003){ref-type="supplementary-material"}**).

Obesity was evaluated according to body mass index (BMI; cut off \>22 kg/m^2^), BMI percentile (BMIp; cut off \>85% (Ogden *et al*, 2010)), and obesity index (OI; cut off \>20%). BMI was calculated as follows: body weight (kg)/{height (m)}^2^. The exclusive software (NordiFIT ver 3.0; Novo Nordisk, Denmark) was used to calculate BMIp. OI was calculated using the formulae provided by the Japanese Society for Paediatric Endocrinology (**Table G in [S1 File](#pone.0136428.s003){ref-type="supplementary-material"}**). The obesity rate according to the age group in this cohort is shown in **[S2 Fig](#pone.0136428.s002){ref-type="supplementary-material"}**.

Statistical analysis {#sec006}
--------------------

Multiple logistic regression model was used to investigate risk factors that were associated with L-asp-related hyperglycaemia, A factor was included in the model if the two-tailed P value for its univariate association with L-asp-related hyperglycaemia was P\<0.05. Factors that were significant on multivariable analysis (P\<0.05) were included in the final model; results were reported using adjusted odds ratios with 95% confidence intervals (95% CIs). Other comparisons were performed using the **χ** ^**2**^, Fisher's exact, and Mann-Whitney U tests as appropriate. P \<0.05 were considered significant.

Results {#sec007}
=======

Clinical characteristics of patients who developed L-asp-related hyperglycemia {#sec008}
------------------------------------------------------------------------------

The clinical characteristics of the patients who developed L-asp-related hyperglycemia are summarized in **[Table 2](#pone.0136428.t002){ref-type="table"}**. Sixty-nine of 1,176 (5.9%) patients experienced L-asp-related hyperglycemia and the hyperglycemic patients were significantly older (9.3 ± 4.1 vs 5.6 ± 3.8 years, P\<0.01). Sex, initial WBC counts, immunophenotype and the presence of extramedullary disease were not statistically different between two groups. Down syndrome tends to be more in hyperglycemic patients, although it is not statistically significant (P = 0.05). A total of 75 L-asp related hyperglycemia events occurred in 69 patients. The grade, therapeutic phase, and risk group of the 75 events are summarized in **Table H in [S1 File](#pone.0136428.s003){ref-type="supplementary-material"}**. Fifty and 25 events were classified as grade 3 and grade 4 hyperglycemia, respectively. Seventeen (22.7%) events developed during the induction phase, 11 (14.7%) during the re-induction phase, 45 (60%) during the maintenance phase, and two during other phases. Forty-seven of 75 events (62.7%) occurred in the HR group treated with protracted administration of L-asp in maintenance phase. Three of the 69 patients (two HR and one T) switched to a protocol that did not contain L-asp because of severe hyperglycemia that developed during the maintenance phase.

10.1371/journal.pone.0136428.t002

###### Comparison of patient characteristics with or without hyperglycemia (69 cases *vs*. 1,107 cases).
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  Feature at diagnosis                   Category                Number of patients                                
  -------------------------------------- ----------------------- -------------------- ------------------ --------- ---------
  Age at onset (year)                    Average ± SD (median)   9.3 ± 4.1 (10)       5.6 ± 3.8 (4)      \< 0.01   
  Sex                                    Female                  34                   492                0.43      
  Male                                   35                      615                                               
  Immunophenotype                        B-cell                  62                   970                0.99      
  Mixed                                  2                       36                                                
  T-cell                                 5                       94                                                
  Undifferentiated                       0                       7                                                 
  Leukocyte count at onset (× 10^9^/L)   Range (median)          0.60--509 (7.40)     0.37--819 (7.50)   0.41      
  Extramedullary disease                 Absent                  65                   1,074              0.34      
  Present                                4                       33                                                
  Obesity                                BMI                     \< 22%               59                 1,008     \< 0.01
  ≥ 22%                                  8                       29                                                
  BMIp                                   \< 85%                  50                   889                0.01      
  ≥ 85%                                  17                      148                                               
  Obesity index                          \< 20%                  57                   978                \< 0.01   
  ≥ 20%                                  10                      59                                                
  No data                                                        2                    72                           
  Down syndrome                          Absent                  65                   1,088              0.05      
  Present                                4                       19                                                

Risk factors for L-asp-related hyperglycemia {#sec009}
--------------------------------------------

Univariate analysis revealed that L-asp-related hyperglycemia correlated with older age (older than 5 years, 10 years and 15 years), type of protocol (HR and ER), higher BMI (≥22 kg/m^2^), higher BMIp (≥85%), higher OI (≥20%) and Down syndrome (P\<0.05; **[Table 3](#pone.0136428.t003){ref-type="table"}**), which are consistent with previous reports \[[@pone.0136428.ref015], [@pone.0136428.ref016], [@pone.0136428.ref019], [@pone.0136428.ref020]\]. Because more than half events developed in maintenance phase, univariate analysis was also performed for L-asp-related hyperglycemia during the induction, re-induction, and maintenance phases (**[Table 3](#pone.0136428.t003){ref-type="table"}**). The analysis also showed that older age (older than 10 and 15 years) and higher BMI (≥22 kg/m^2^) correlated with L-asp-related hyperglycemia during the induction phase (P\<0.05). Type of protocol was not associated with L-asp related hyperglycemia in induction phase just because the dose and schedule of L-asp administration was the same in all risk groups. Univariate analysis also showed that older age (older 5 and 10 years), female patient, higher BMI, and higher OI also correlated with hyperglycemia during the maintenance phase (P\<0.05), but did not show any significant risk factors related to L-asp-related hyperglycemia in the re-induction phase, partly because the number of events (n = 11) was small. Multivariate analysis revealed that older age (older than10 years) was associated with L-asp-related hyperglycemia during the entire treatment and the maintenance phase. However, BMI (≥22 kg/m^2^) was not associated with L-asp-related hyperglycemia (**[Table 4](#pone.0136428.t004){ref-type="table"}**). These findings suggested that protracted administration of L-asp with PSL was risk factor of hyperglycemia in the patients older than 10 years irrespective of obesity. On the other hand, either older age or higher BMI was not associated with L-asp-related hyperglycemia in induction phase, partly because the number of events was small (n = 17) (**[Table 4](#pone.0136428.t004){ref-type="table"}**). However, 14 of 17 patients were older than 10 years and only two of 17 patients showed higher BMI.

10.1371/journal.pone.0136428.t003

###### Univariate analysis of L-asp-related hyperglycemia.
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                                         During entire treatment   Induction phase   Maintenance phase                                                                            
  -------------------- ----------------- ------------------------- ----------------- ------------------- --------------- --------------- -------- --------------- --------------- --------
  Age at onset (yrs)                                                                                                                                                              
                       1--4 vs 5--18     1.000                                                           1.000                                    1.000                           
                       4.534             2.441--8.422              \<0.0001          1.330               1.330--3.500    0.564           11.157   3.323--37.462   \<0.0001        
                       1--9 vs 10--18    1.000                                                           1.000                                    1.000                           
                       5.442             3.308--8.953              \<0.0001          3.731               1.424--9.778    0.0074          7.299    3.882--15.247   \<0.0001        
                       1--14 vs 15--18   1.000                                                           1.000                                    1.000                           
                       3.656             1.455--9.183              0.006             7.629               2.082--27.954   0.002           1.685    0.493--5.759    0.405           
  Sex                                                                                                                                                                             
                       female            1.000                                                           1.000                                    1.000                           
                       male              0.824                     0.506--1.340      0.4342              1.158           0.432--3.453    0.7065   0.519           0.281--0.957    0.0358
  Risk                                                                                                                                                                            
                       SR                1.000                                                           1.000                                    \-              \-              \-
                       HR                3.670                     1.761--7.646      0.0005              0.628           0.217--2.630    0.6601   1.000                           
                       ER                4.735                     1.974--11.361     0.0005              2.043           0.434--7.825    0.4069   1.001           0.449--2.234    0.9981
                       F                 1.148                     0.243--5.421      0.8620              \-              \-              \-       \-              \-              \-
                       T                 2.264                     0.679--7.547      0.1833              1.667           0.330--8.415    0.5363   0.286           0.067--1.216    0.0902
  BMI                                                                                                                                                                             
                       \< 22%            1.000                                                           1.000                                    1.000                           
                       ≥ 22%             4.713                     2.064--10.761     0.0002              6.636           1.822--24.177   0.0041   6.716           2.385--18.913   0.0003
  BMI percentile                                                                                                                                                                  
                       \< 85%            1.000                                                           1.000                                    1.000                           
                       ≥ 85%             2.042                     1.147--3.637      0.0153              2.414           0.839--6.945    0.1021   1.931           0.953--3.911    0.0677
  Obesity index                                                                                                                                                                   
                       \< 20%            1.000                                                           1.000                                    1.000                           
                       ≥20%              2.908                     1.413--5.984      0.0037              3.315           0.930--11.823   0.0647   2.805           1.160--6.783    0.0221
  Down syndrome                                                                                                                                                                   
                       Absent            1.000                                                           1.000                                    1.000                           
                       Present           3.286                     1.086--9.946      0.0352              2.975           0.378--23.430   0.3005   3.853           0.755--19.671   0.1049

BMI, body mass index; CI, Confidence interval; ER, extremely high risk; F, induction failure; HR, high risk; SD, standard deviation; SR, standard risk; T, T-cell type.

10.1371/journal.pone.0136428.t004

###### Multivariate analysis of L-asp-related hyperglycemia.
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                                During entire treatment   Induction phase   Maintenance phase                                                            
  -------------------- -------- ------------------------- ----------------- ------------------- ------- --------------- -------- ------- --------------- ----------
  Age at onset (yrs)                                                                                                                                     
                       \< 10    1.000                                                           1.000                            1.000                   
                       ≥ 10     3.824                     2.092--6.988      \<0.0001            2.796   0.970--8.062    0.0570   6.415   3.116--13.205   \<0.0001
  Sex                                                                                                                                                    
                       Female                                                                                                    1.000                   
                       male                                                                                                      0.567   0.291--1.104    0.0949
  Risk                                                                                                                                                   
                       SR       1.000                                                           1.000                            1.000                   
                       HR       1.801                     0.760--4.267      0.1815              \-      \-              \-       \-      \-              \-
                       ER       2.292                     0.851--6.172      0.1008              \-      \-              \-       \-      \-              \-
                       T        0.538                     0.103--2.813      0.4624              \-      \-              \-       \-      \-              \-
                       F        1.456                     0.391--5.423      0.5775              \-      \-              \-       \-      \-              \-
  BMI                                                                                                                                                    
                       \< 22%   1.000                                                           1.000                            1.000                   
                       ≥ 22%    1.813                     0.727--4.522      0.2022              3.583   0.867--14.804   0.0779   2.597   0.842--8.015    0.0969

BMI, body mass index; CI, Confidence interval; ER, extremely high risk; F, induction failure; HR, high risk; SD, standard deviation; SR, standard risk; T, T-cell type.

L-asp-related hyperglycemia does not affect prognosis {#sec010}
-----------------------------------------------------

To evaluate the prognostic significance of L-asp-related hyperglycemia, we performed univariate and multivariate analyses of HR patients (n = 416). Univariate analysis revealed that older age (≥10) and development of L-asp-related hyperglycemia during the maintenance phase were associated with poorer event-free survival (EFS). However, multivariate analysis revealed that only older age (≥10) was associated with poor EFS (**[Table 5](#pone.0136428.t005){ref-type="table"}**).

10.1371/journal.pone.0136428.t005

###### Univariate and multivariate analyses of outcomes for patients in the high risk group.
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                                                  Univariate analysis   Multivariate analysis                                                 
  ------------------------------------- --------- --------------------- ----------------------- ------------ -------- ------- ------- ------- --------
  Hyperglycaemia in induction phase                                                                                                           
                                        Absent    1.000                                                               1.000                   
                                        Present   5.953                 0.525                   67.446       0.1498   \-      \-      \-      \-
  Hyperglycemia in re-induction phase                                                                                                         
                                        Absent    1.000                                                               1.000                   
                                        Present   \< 0.001              \< 0.001                \> 999.999   0.9857   \-      \-      \-      \-
  Hyperglycemia in maintenance phase                                                                                                          
                                        Absent    1.000                                                               1.000                   
                                        Present   3.413                 1.362                   8.557        0.0088   2.187   0.807   5.929   0.1242
  Age at onset                                                                                                                                
                                        \< 10     1.000                                                               1.000                   
                                        ≥ 10      3.060                 1.478                   6.332        0.0026   2.514   1.145   5.516   0.0215
  Sex                                                                                                                                         
                                        Female    1.000                                                               1.000                   
                                        Male      1.630                 0.769                   3.456        0.2022   \-      \-      \-      \-
  BMI                                                                                                                                         
                                        \< 22%    1.000                                                               1.000                   
                                        ≥ 22%     2.684                 0.554                   13.004       0.2200   \-      \-      \-      \-
  BMI percentile                                                                                                                              
                                        \< 85%    1.000                                                               1.000                   
                                        ≥ 85%     0.886                 0.328                   2.396        0.8122   \-      \-      \-      \-
  Obesity index                                                                                                                               
                                        \< 20%    1.000                                                               1.000                   
                                        ≥ 20%     0.921                 0.208                   4.086        0.9142   \-      \-      \-      \-
  Down syndrome                                                                                                                               
                                        Absent    1.000                                                               1.000                   
                                        Present   3.922                 0.758                   20.283       0.1031   \-      \-      \-      \-

BMI, body mass index; CI, Confidence interval

Discussion {#sec011}
==========

Previous studies of pediatric ALL patients show that older age (≥10 years) at disease onset and obesity are risk factors for L-asp-related hyperglycemia, especially during the induction phase \[[@pone.0136428.ref015], [@pone.0136428.ref016], [@pone.0136428.ref019], [@pone.0136428.ref020]\]. Pui et al retrospectively performed multivariate analysis for 421 children treated at St. Jude Children's Hospital and identified four independent risk factors for the development of L-asp-related hyperglycemia during induction therapy: 1) age \>10 years, 2) obesity (defined as ≥20% over ideal weight), 3) Down syndrome, and 4) having a first- or second-degree relative with diabetes mellitus \[[@pone.0136428.ref015]\]. Sonabend et al also used univariate analysis to identify four risk factors for the development of overt hyperglycemia (serum glucose\>200 mg/dl) during the induction phase: 1) age \>10 years, 2) BMIp ≥85%, 3) high risk according to the National Cancer Institute, and 4) use of prednisolone \[[@pone.0136428.ref020]\]. Lowas et al performed multivariate analysis on 33 (20.3%) of 162 patients who developed transient hyperglycemia (BS \>200 mg/dl) during the induction phase and showed that older age (≥10 years) and higher BMIp (≥85%) were independent risk factors for developing transient hyperglycemia \[[@pone.0136428.ref019]\].

Here we analyzed 1,176 pediatric ALL patients treated according to the JACLS ALL-02 protocol. This is the largest cohort in which L-asp-related hyperglycemia has been investigated. We found that L-asp-related hyperglycemia occurred in 69 of 1,176 (5.9%) patients. Multivariate analysis identified older age (≥10 years) as the sole independent risk factor for L-asp-related hyperglycemia. The unique finding of this study was that obesity was not an independent risk factor (**[Table 4](#pone.0136428.t004){ref-type="table"}**). In our protocol, none of the SR patients (who did not receive L-asp during the maintenance phase) were older than 10 years-of-age. Thus, the high incidence of L-asp-related hyperglycemia in older patients may be associated with prolonged use of L-asp combined with prednisolone during the maintenance phase (**Tables A-E in [S1 File](#pone.0136428.s003){ref-type="supplementary-material"}**), as 45 of 75 events (60%) occurred during this phase (**Table H in [S1 File](#pone.0136428.s003){ref-type="supplementary-material"}**). Accordingly, multivariate analysis identified a strong correlation between older age (≥10 years) and L-asp-related hyperglycemia during the maintenance phase (P\<0.01, **[Table 4](#pone.0136428.t004){ref-type="table"}**). Because protracted administration of L-asp in maintenance phase was not popular in other pediatric ALL protocols, hyperglycemia in maintenance phase seemed to be peculiar in our protocol. Thus, current national protocol for pediatric ALL does not employ protracted administration of L-asp in maintenance phase in Japan. On the other hand, the overall incidence of L-asp-related hyperglycemia during the induction phase was 1.4% (17 of 1,176), which was lower than those in the previous reports (10--15%) \[[@pone.0136428.ref015],[@pone.0136428.ref016],[@pone.0136428.ref019],[@pone.0136428.ref020]\]. Relatively low dose of concomitant PSL (40 mg/m^2^) use and no administration of DEX might explain the low frequency of L-asp related hyperglycemia in induction phase in this study.

L-asp inhibits insulin synthesis by the pancreatic β cells, and L-asp-related hyperglycemia may occur readily in patients with insulin resistance \[[@pone.0136428.ref021]\]. Insulin resistance increases during adolescence partly because of increased growth hormone secretion \[[@pone.0136428.ref016], [@pone.0136428.ref022]--[@pone.0136428.ref024]\], which may explain why L-asp-related hyperglycemia occurs more often in older pediatric patients. Obesity is also related to insulin resistance through increased secretion of adipocytokines such as leptin and adiponectin \[[@pone.0136428.ref025], [@pone.0136428.ref026]\]. Increased visceral fat contributes to insulin resistance by decreasing blood adiponectin levels \[[@pone.0136428.ref026]\]. Because the pediatric standard of obesity according to BMI changes substantially with age and height, OI or BMIp may be more accurate indicators of obesity in a pediatric cohort \[[@pone.0136428.ref027]\]. Thus, we used these measures to analyze the effect of obesity more precisely in this study. However, multivariate analysis revealed that none of these measures of obesity were associated with L-asp-related hyperglycemia. The reason why obesity was not associated with occurrence of L-asp-related hyperglycemia is unclear. In this analysis, we evaluated three kinds of measures related to obesity; BMI, BMIp and OI, however, in all evaluations, there were clearly low frequency of obese patients in our cohort (**Tables [1](#pone.0136428.t001){ref-type="table"} and [2](#pone.0136428.t002){ref-type="table"}**). Thus, the small number of the obese patients might cause different result from those in previous studies. Considering insulin resistance is deeply associated with L-asp-related hyperglycemia, the limitation of this study is that we could not evaluate serum biomarker of insulin resistance such as leptin, adiponectin, GH and IGF1. Because the age or BMI is just surrogate marker of insulin resistance, we should use more reliable biomarker(s) to evaluate personal insulin resistance in these studies.

Previous studies demonstrate that older age is a risk factor for various adverse events associated with L-asp treatment for pediatric ALL, including pancreatitis, thrombotic complications, hypertriglyceridemia, and hyperglycemia \[[@pone.0136428.ref028], [@pone.0136428.ref029]\]. However, pediatric protocols are recommended worldwide for AYA with ALL, as several recent studies show that pediatric protocols with intensive L-asp therapy are associated with EFS and disease-free survival in AYA patients with ALL \[[@pone.0136428.ref007], [@pone.0136428.ref008]\]. Although retrospective studies show that the prognosis for AYAs with ALL treated with a pediatric protocol is excellent \[[@pone.0136428.ref030]\], L-asp-related side effects should be monitored carefully in this age group.

Finally, we found that multivariate analysis revealed that L-asp-related hyperglycemia did not correlate with poor prognosis (**[Table 5](#pone.0136428.t005){ref-type="table"}**). The excellent supportive care in our study ensured that most of the patients (66 of 69, 95.7%) completed the protocol. A univariate analysis performed by Sonabend et al showed that pediatric ALL patients with overt hyperglycemia (serum glucose \> 200 mg/dl) had a 6.2 times greater risk of death \[[@pone.0136428.ref020]\]. Although they indicated that the relationship between hyperglycemia and death was unclear, this may be due to a high rate of NCI high risk patients among hyperglycemic group, suggesting that hyperglycemia might be just confounding factor for poor outcome.

In summary, we analyzed 1,176 pediatric ALL patients to identify risk factors for L-asp-related hyperglycemia. Multivariate analysis identified older age at onset (≥10 years) as the sole independent risk factor, suggesting that prolonged administration of L-asp combined with prednisolone may cause increased hyperglycemia in patients ≥10 years-of-age due to age-related insulin resistance. However, obesity (as measured by BMI, BMIp, and OI) was not correlated with L-asp-related hyperglycemia. These findings suggest that careful monitoring of hyperglycemia is essential when treating AYA with ALL, irrespective of obesity, using a pediatric protocol that includes intensive L-asp therapy.

Supporting Information {#sec012}
======================

###### Risk classification according to the JACLS ALL-02 protocol.

ALL, acute lymphoblastic leukaemia; AUL, Acute undifferentiated leukaemia; CNS, central nervous system; ER, extremely high risk; F, induction failure; HR, high risk; IT, intrathecal therapy; M1, blasts \< 5% in bone marrow; M2, 5% ≤ blasts \< 25% in bone marrow; M3, blasts ≥ 25% in bone marrow; MTX, methotrexate; PGR, PSL good response; Ph-ALL, Philadelphia chromosome (t(9;22))-positive ALL; PPR, PSL poor response; PSL, prednisolone; SR, standard risk; T T cell type ALL; WBC, white blood cell.

(TIF)

###### 

Click here for additional data file.

###### Obesity rate according to the age in this study.

Total number is 1,104, which has the data of height and weight. The rate of obesity is roughly around 10%, and at the most 20%. BMI, body mass index, BMIp, BMI percentile; n, number; OI, obesity index.

(TIF)

###### 

Click here for additional data file.

###### JACLS ALL-02 standard risk (SR) protocol (Table A), JACLS ALL-02 high risk (HR) protocol (CNS negative) (Table B), JACLS ALL-02 extremely high risk (ER) protocol (CNS negative) (Table C), JACLS ALL-02 T-cell protocol (CNS negative) (Table D), JACLS ALL-02 F protocol (CNS negative) (Table E), Comparison of patient characteristics with and without height and weight data (Table F), Formulae used to calculate the obesity index (Table G), Development and severity of hyperglycemia according to patient risk (Table H).

(DOCX)

###### 

Click here for additional data file.
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